Business Context and Reporting Period
This Form 8-K was filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on December 28, 2022, reporting an event that occurred on December 27, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol "GRAY".
Key Financial Metrics
This filing is a current report regarding a listing status event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the receipt of a written notice from The Nasdaq Stock Market stating that the Company no longer complies with the minimum bid price requirement for continued listing. Specifically, the closing bid price of the Company's common stock remained below $1.00 per share for 30 consecutive trading days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period to regain compliance, ending on June 26, 2023.
- Requirements: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
- Extension Options: If compliance is not met by the initial deadline, the Company may be eligible for an additional 180-day period if it elects to transfer to The Nasdaq Capital Market and meets specific market value standards.
- Risks: There is no assurance that the Company will regain compliance or that Nasdaq will grant further extensions. Failure to comply within the allowed periods will result in the delisting of the Common Stock.
- Management Action: The Company intends to monitor the stock price and consider available options to resolve the noncompliance.
Investor Verification Checklist
- Verify the current closing bid price of Graybug Vision, Inc. (GRAY) to assess progress toward the $1.00 threshold.
- Monitor subsequent filings for any announcements regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.
- Check for any updates on the Company's intent to transfer to The Nasdaq Capital Market if the initial compliance period expires.
- Review the Company's most recent 10-K or 10-Q filings for financial health indicators, as this 8-K contains no financial data.